Roots Analysis has announced the addition of “Spatial Genomics, Transcriptomics and Proteomics Solutions Market, 2022-2035” report to its list of offerings.
Key Market Insights
§ Presently, more than 70 spatial omics solutions are either commercialized / underdeveloped for the spatial phenotyping and spatial profiling of cellular landscape.
§ 45 industry and non-industry players claim to offer spatial genomics, transcriptomics and proteomics solutions.
§ Majority (72%) of the solution providers are based in North America, followed by those headquartered in Europe (22%). A large proportion (50%) of these companies are large players, followed by small (30%) and mid-sized firms (20%).
§ The rising interest in this rapidly evolving domain can be validated by the partnerships inked in recent years; majority of the deals were signed for technology / platform integration purposes
§ Grants worth over USD 20 million have been awarded to support research on spatial omics solutions, since 2018, of which, 38% of the total number of grants were provided by the National Institutes of Health (NIH).
§ North America is anticipated to capture larger share of market by 2035 and is estimated to be worth USD 9.61 billion by 2035, growing at a CAGR of 11.5%.
§ Our estimates suggest that the overall market is likely to be driven by the revenues generated through the sales of spatial omics instruments in the foreseen future due to their high cost. Further, the share of consumables and software is expected to grow at a relatively faster pace (12.7%), during the given period.
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Spatial Biology
3.3. Overview of Spatial Omics Solutions
3.2.1. Historical Overview of Spatial Omics Solutions
3.2.2. Features of Spatial Omics Solutions
3.2.3. Workflow of Spatial Omics Instruments
3.2.4. Computational Methods for Spatial Omics
3.2.5. Application Areas of Spatial Omics
3.4. Concluding Remarks
4. SPATIAL OMICS SOLUTIONS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. List of Spatial Omics Solutions
4.2.1. Analysis by Commercial Availability
4.2.2. Analysis by Type of Solution(s) Offered
4.2.3. Analysis by Type of Sample(s) Analyzed
4.2.4. Analysis by Supporting Labware
4.2.5. Analysis by Type of Molecule(s) Analyzed
4.2.6. Analysis by Detection Method(s) Used
4.2.7. Analysis by Maximum Plex Level
4.2.8. Analysis by Quantification Capability
4.2.9. Analysis by Research Area(s)
4.2.10. Analysis by Application Area(s)
4.2.11. Analysis by Compatible Sample Source(s)
4.2.12 Analysis by Compatible Sample Source(s) and Type of Sample(s) Analyzed
4.2.13 Analysis by Quantification Capability and Type of Molecule(s) Analyzed
4.2.13 Analysis by Detection Method(s) Used and Maximum Plex Level
4.3. Spatial Omics Solution Providers: List of Players
4.3.1. Analysis by Type of Players
4.3.2. Analysis by Year of Establishment
4.3.3. Analysis by Player Size
4.3.4. Analysis by Location of Headquarters
4.3.5. Analysis by Company Ownership
4.3.6. Analysis by Year of Establishment and Location of Headquarters
4.3.7. Analysis by Player Size and Location of Headquarters
4.3.8. Analysis by Leading Players
4.4. Spatial Omics Solutions: List of Kits
4.5. Spatial Omics Solutions: Funding and Investments
5. SPATIAL OMICS SOLUTION PROVIDERS: PRODUCT COMPETITIVENESS ANALYSIS
5.1 Chapter Overview
5.2 Assumptions / Key Parameters
5.3 Methodology
5.4 Product Competitiveness Analysis: Spatial Omics Solution Providers
5.4.1 Peer Group I: Small Companies
5.4.2. Peer Group II: Mid-sized Companies
5.4.3. Peer Group III: Large Companies
6. SPATIAL OMICS SOLUTIONS: COMPANY PROFILES
6.1. Chapter Overview
6.2. Spatial Omics Analysis Solution Providers: North America
6.2.1. 10X Genomics
6.2.1.1. Company Overview
6.2.1.2. Financial Information
6.2.1.3. Product Portfolio
6.2.1.4. Recent Developments and Future Outlook
6.2.2. Akoya Biosciences
6.2.2.1. Company Overview
6.2.2.2. Financial Information
6.2.2.3. Product Portfolio
6.2.2.4. Recent Developments and Future Outlook
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Product Portfolio
6.2.3.4. Recent Developments and Future Outlook
6.2.4. Canopy Biosciences
6.2.4.1. Company Overview
6.2.4.2 Financial Information
6.2.4.3. Product Portfolio
6.2.4.4. Recent Developments and Future Outlook
6.2.5. NanoString Technologies
6.2.5.1. Company Overview
6.2.5.2. Product Portfolio
6.2.5.3. Recent Developments and Future Outlook
6.2.6.1. Company Overview
6.2.6.2. Product Portfolio
6.2.6.3. Recent Developments and Future Outlook
6.3. Spatial Omics Analysis Solution Providers: Europe
6.3.1.1. Company Overview
6.3.1.2. Product Portfolio
6.3.1.3. Recent Developments and Future Outlook
6.3.2. Molecular Machines & Industries (MMI)
6.3.2.1. Company Overview
6.3.2.2. Product Portfolio
6.3.2.3. Recent Developments and Future Outlook
6.3.3. Resolve Biosciences
6.3.3.1. Company Overview
6.3.3.2. Product Portfolio
6.3.3.3. Recent Developments and Future Outlook
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Spatial Omics Solutions: List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Type of Partner
7.3.4. Analysis by Year of Partnership and Type of Partner
7.3.5. Analysis by Type of Partnership and Type of Partner
7.3.6. Analysis by Therapeutic Area
7.3.7. Intercontinental and Intracontinental Agreements
7.3.8.
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
Telugu